Pay in 4 interest-free payments of $6.62 Learn more
Ships within 48 hours · Estimated delivery Sep 4 - Sep 9
But whats actually going on behind the scenes
As of mid-2025, approximately 1012 million Americans are actively filling GLP-1 prescriptions for weight management or diabetes treatment, according to IQVIA patient data with Gallup and RAND surveys suggesting as many as 1112% of US adults report current or recent use
Semaglutide & Tirzepatide is a subcutaneous injection, meaning it is administered into the fatty tissue just beneath the skin
The GLP-1 receptor class has demonstrated remarkable durability in clinical use
According to NICE Technology Appraisal (TA875), Wegovy is recommended for adults with a BMI of at least 35 kg/m (or lower thresholds for certain ethnic groups) who have at least one weight-related comorbidity
US$ 29.40
US$ 27.59
US$ 24.76
